Finance
e-Newsletter
Intelligence Unit Special Reports Special Events Subscribe Sponsored Departments Follow Us

Twitter Facebook LinkedIn RSS

Health reform in limbo, top drug lobbyist quits

New York Times, February 12, 2010

Billy Tauzin, one of the highest paid lobbyists in Washington, is resigning as president of the pharmaceutical industry's trade group amid internal disputes over its pact with the White House to trade political support for favorable terms in the proposed healthcare overhaul, the New York Times reports. Tauzin brokered the deal last summer with the White House and Max Baucus, chairman of the Senate Finance Committee, to limit the drug industry's total costs under the proposed healthcare overhaul to $80 billion over 10 years.